--- title: "Glow (GHK-Cu / BPC-157 / TB-500)" canonical_url: https://bestpeptidecalculator.app/library/glow description: "Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Glow (GHK-Cu / BPC-157 / TB-500) Glow (GHK-Cu / BPC-157 / TB-500), also called GHK-Cu + BPC-157 + TB-500 or GLOW blend, is a regenerative-cosmetic blend in the Multi-Mechanism Repair class. Glow is a compounded blend rather than a single compound, combining GHK-Cu, BPC-157 and TB-500. Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them. Also known as: GHK-Cu + BPC-157 + TB-500, GLOW blend. Categories: Muscle/Recovery, Cosmetic, Experimental. ## Classification - Type: Regenerative-cosmetic blend - Mechanism class: Multi-Mechanism Repair - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism Glow is a compounded blend rather than a single compound, combining GHK-Cu, BPC-157 and TB-500. Each component has its own proposed mechanism: GHK-Cu binds copper and modulates matrix metalloproteinase expression and collagen synthesis in skin models; BPC-157 has been reported in animal work to promote angiogenesis through VEGFR2 and FAK signalling and to modulate the nitric oxide system; TB-500 corresponds to the actin-binding region of thymosin beta-4 and is associated with cell migration and wound closure in preclinical models. The blend has no mechanism of its own beyond those, and no controlled trial has evaluated the combination as a product. Component interactions and relative dosing are not characterised. Targets: Extracellular matrix, Angiogenic pathways (component-dependent). Origin: Commercial multi-peptide blend. ## Properties - Sequence: GHK-Cu: Gly-His-Lys-Cu; BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (thymosin β4 17–23 fragment, as TB-500 is usually sold; some vendors supply full-length thymosin β4) - Molecular formula: Varies - Molecular weight: Varies - Half-life: Varies by component ## Evidence - Evidence level: Insufficient Evidence - Highest documented: Lab & animal studies - Human trials: 0 - Controlled human trials: 0 - Preclinical sources: 1 - Latest source: 2026 No human dose is established for this compound. Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. 2006. Human study (early or uncontrolled). Population: Patients after circumoral CO2 laser skin resurfacing (13 completed). No significant difference in erythema, wrinkles or skin quality on objective or blinded evaluation; patient-rated satisfaction was higher with GHK-Cu. Research on a related compound, not this one. Limitations: Studied an analog, not Glow (GHK-Cu / BPC-157 / TB-500) itself [Source](https://pubmed.ncbi.nlm.nih.gov/16847171/) 2. NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair. Human study (early or uncontrolled). Population: Adults with acute hamstring muscle strain (planned n=120). Hamstring muscle strain repair; no results posted. Research on a related compound, not this one. Limitations: Studied an analog, not Glow (GHK-Cu / BPC-157 / TB-500) itself; Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07437547) 3. NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. Human study (early or uncontrolled). Population: Adults with stable atherosclerotic cardiovascular disease (planned n=80). Cardiovascular biomarkers; no results posted. Research on a related compound, not this one. Limitations: Studied an analog, not Glow (GHK-Cu / BPC-157 / TB-500) itself; Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07487363) 4. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. 2026. Preclinical: animal or lab study. Population: Male Sprague-Dawley rats after Achilles tendon transection and repair (n=32, 8 per group). Both peptides alone improved tendon histology, and TB-500 alone improved load to failure; the combination gave no added benefit over either alone. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/42542926/) ### Registered trials - [NCT07437547](https://clinicaltrials.gov/study/NCT07437547) - [NCT07487363](https://clinicaltrials.gov/study/NCT07487363) ## Safety Side effects: Irritation; Headache. Risks: Copper imbalance; Limited blend data. Contraindications: Copper allergy. Human safety basis: No controlled human safety data Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use.. ## Regulatory status Glow (GHK-Cu / BPC-157 / TB-500) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - Availability: Research-Only ## Frequently asked questions ### What is Glow (GHK-Cu / BPC-157 / TB-500)? Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them. ### How does Glow (GHK-Cu / BPC-157 / TB-500) work? Glow is a compounded blend rather than a single compound, combining GHK-Cu, BPC-157 and TB-500. Each component has its own proposed mechanism: GHK-Cu binds copper and modulates matrix metalloproteinase expression and collagen synthesis in skin models; BPC-157 has been reported in animal work to promote angiogenesis through VEGFR2 and FAK signalling and to modulate the nitric oxide system; TB-500 corresponds to the actin-binding region of thymosin beta-4 and is associated with cell migration and wound closure in preclinical models. ### Is Glow (GHK-Cu / BPC-157 / TB-500) FDA approved? No. Glow (GHK-Cu / BPC-157 / TB-500) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. ### What is the half-life of Glow (GHK-Cu / BPC-157 / TB-500)? Reported half-life for Glow (GHK-Cu / BPC-157 / TB-500) is Varies by component. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied. ### What is the amino acid sequence of Glow (GHK-Cu / BPC-157 / TB-500)? Glow is a blend, not a single peptide. Its components are GHK-Cu (Gly-His-Lys copper complex), BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500, which is usually the acetylated thymosin β4 fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln rather than the full 43-residue protein. There is no single molecular formula; composition depends on the vial. ### What peptides are similar to Glow (GHK-Cu / BPC-157 / TB-500)? Compounds most often compared with Glow (GHK-Cu / BPC-157 / TB-500) include GHK-Cu (Copper Peptide), BPC-157, TB-500 (Thymosin Beta-4 fragment) and KLOW (GHK-Cu / KPV / BPC-157 / TB-500). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list) - [Component evidence (GHK-Cu (Copper Peptide)) — Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?](https://pubmed.ncbi.nlm.nih.gov/39795193/) - [Component evidence (GHK-Cu (Copper Peptide)) — Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data](https://pubmed.ncbi.nlm.nih.gov/29986520/) - [Component evidence (BPC-157) — Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review](https://pubmed.ncbi.nlm.nih.gov/40005999/) - [Component evidence (BPC-157) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/40756949/)